Vascular Biogenics Probability of Future Stock Price Finishing Over 5.65

VBLTDelisted Stock  USD 0.16  0.01  5.88%   
Vascular Biogenics' future price is the expected price of Vascular Biogenics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Vascular Biogenics performance during a given time horizon utilizing its historical volatility. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
  
Please specify Vascular Biogenics' target price for which you would like Vascular Biogenics odds to be computed.

Vascular Biogenics Target Price Odds to finish over 5.65

The tendency of Vascular Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 5.65  or more in 90 days
 0.16 90 days 5.65 
close to zero percent
Based on a normal probability distribution, the odds of Vascular Biogenics to move over $ 5.65  or more in 90 days from now is close to zero percent (This Vascular Biogenics probability density function shows the probability of Vascular Stock to fall within a particular range of prices over 90 days) . Probability of Vascular Biogenics price to stay between its current price of $ 0.16  and $ 5.65  at the end of the 90-day period is close to 99 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.26 . This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Vascular Biogenics will likely underperform. Additionally Vascular Biogenics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
   Vascular Biogenics Price Density   
       Price  

Predictive Modules for Vascular Biogenics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vascular Biogenics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Vascular Biogenics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.160.160.16
Details
Intrinsic
Valuation
LowRealHigh
0.150.150.18
Details
Naive
Forecast
LowNextHigh
0.140.140.14
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.140.220.30
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Vascular Biogenics. Your research has to be compared to or analyzed against Vascular Biogenics' peers to derive any actionable benefits. When done correctly, Vascular Biogenics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Vascular Biogenics.

Vascular Biogenics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Vascular Biogenics is not an exception. The market had few large corrections towards the Vascular Biogenics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vascular Biogenics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vascular Biogenics within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
-0.77
β
Beta against NYSE Composite1.26
σ
Overall volatility
0.03
Ir
Information ratio -0.12

Vascular Biogenics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vascular Biogenics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vascular Biogenics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Vascular Biogenics is now traded under the symbol NTBL. Please update your portfolios or report it if you believe this is an error. Report It!
Vascular Biogenics is not yet fully synchronised with the market data
Vascular Biogenics has some characteristics of a very speculative penny stock
Vascular Biogenics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 658 K. Net Loss for the year was (32.3 M) with profit before overhead, payroll, taxes, and interest of 554 K.
Vascular Biogenics currently holds about 34.15 M in cash with (31.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 13.0% of the company outstanding shares are owned by insiders

Vascular Biogenics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vascular Stock often depends not only on the future outlook of the current and potential Vascular Biogenics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vascular Biogenics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding77.6 M
Cash And Short Term Investments20.7 M

Vascular Biogenics Technical Analysis

Vascular Biogenics' future price can be derived by breaking down and analyzing its technical indicators over time. Vascular Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Vascular Biogenics. In general, you should focus on analyzing Vascular Stock price patterns and their correlations with different microeconomic environments and drivers.

Vascular Biogenics Predictive Forecast Models

Vascular Biogenics' time-series forecasting models is one of many Vascular Biogenics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Vascular Biogenics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Vascular Biogenics

Checking the ongoing alerts about Vascular Biogenics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Vascular Biogenics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Vascular Biogenics is now traded under the symbol NTBL. Please update your portfolios or report it if you believe this is an error. Report It!
Vascular Biogenics is not yet fully synchronised with the market data
Vascular Biogenics has some characteristics of a very speculative penny stock
Vascular Biogenics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 658 K. Net Loss for the year was (32.3 M) with profit before overhead, payroll, taxes, and interest of 554 K.
Vascular Biogenics currently holds about 34.15 M in cash with (31.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 13.0% of the company outstanding shares are owned by insiders
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Vascular Stock

If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Fundamental Analysis
View fundamental data based on most recent published financial statements